New combo therapy shows promise against HPV-driven head and neck cancer
NCT ID NCT04260126
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study tested a combination of two immunotherapy drugs, PDS0101 and pembrolizumab, in 95 adults with a type of head and neck cancer linked to HPV16 that had returned or spread. The goal was to see if the combination could shrink tumors and improve survival. Participants had to have HPV16-positive, PD-L1-positive tumors and had not received prior checkpoint inhibitor therapy. The results help determine if this approach offers better disease control than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health
Morristown, New Jersey, 07962, United States
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Cleveland Clinic Florida
Weston, Florida, 33331, United States
-
Edinburgh Cancer Centre
Edinburgh, UK EH4 2XU, United Kingdom
-
FDI Clinical Research
San Juan, Puerto Rico, 00927, Puerto Rico
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Marin Cancer Center
Greenbrae, California, 94904, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
-
Medical University of South Carolina Hollings Cancer Center
Charleston, South Carolina, 29425, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
St. James Hospital
Dublin, D08NHY1, Ireland
-
Texas Oncology - Sammons Cancer Center
Dallas, Texas, 75246, United States
-
The Royal Marsden NHS Foundation Trust (Chelsea)
Chelsea, London, SW3 6JJ, United Kingdom
-
The Royal Marsden NHS Foundation Trust (Sutton)
Sutton, Surrey, SM2 5PT, United Kingdom
-
The University of Virginia
Charlottesville, Virginia, 22908, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
-
University of Kentucky Chandler Medical Center - Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
University of Tennessee
Knoxville, Tennessee, 37920, United States
-
West Virginia University
Morgantown, West Virginia, 26506, United States
Conditions
Explore the condition pages connected to this study.